In Most Poorly Controlled Glyburide-Treated Type 2 Diabetic Patients Drug Withdrawal Causes Further Increase in Glycemia not Accompanied by Changes in Insulin Secretion

Abstract

To find out whether the secondary failure of glyburide in type 2 diabetes is complete or partial, we studied 38 patients, age (M ± SD) 69 ± 9 years, suffering from diabetes for 13.5 ± 8.4 years and treated with glyburide for 5 - 13 years, with poor glycemic control (glycohemoglobin 10.6 ± 2.6%). Serum glucose, insulin and C-peptide were assayed before and 1 h and 2 h after a simulated meal load (355 Cal), after which the drug was replaced with placebo for 4 weeks, and the test repeated. After glyburide withdrawal, fasting glycemia increased from 10.3 ± 3.3 to 15.1 ± 4.4 mmol/L(p < 0.001), but in 3/38 patients, it even decreased and in five others the changes were less than ± 2 mmol/L. These changes negatively but only weakly correlated with initial glycemia: r = 0.4123, p < 0.010. The mean post-meal glycemia at 1 h and 2 h increased respectively by 3.3 and 5.9 mmol/L (both p < 0.001). Neither the levels of glycemia nor its changes after the glyburide withdrawal correlated with the levels of, or changes in, insulin or C-peptide. We conclude that in most but not all type-2 diabetic patients, poorly controlled with glyburide, the drug still retains some limited therapeutic effectiveness, and therefore its withdrawal causes further deterioration of control with the almost equal increases in fasting and post-meal levels of glycemia. These changes are not accompanied by decrease in insulin secretion.

Key words

Diabetes type-2 - Sulfonylureas - Glibenclamide - Secondary failure - Insulin secretion